Reduced Effectiveness and Comparable Safety in Biweekly vs. Weekly PEGylated Recombinant Human Growth Hormone for Children With Growth Hormone Deficiency: A Phase IV Non-Inferiority Threshold Targeted Trial

Reduced Effectiveness and Comparable Safety in Biweekly vs. Weekly PEGylated Recombinant Human Growth Hormone for Children With Growth Hormone Deficiency: A Phase IV Non-Inferiority Threshold Targeted Trial

ContextLong-acting recombinant human growth hormone (rhGH) has transformed growth hormone deficiency (GHD) treatment. However, the possibility and rationality for flexible time regimen are pending.ObjectiveWe studied the efficacy of biweekly versus weekly PEGylated rhGH (PEG-rhGH) therapy in GHD chi...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Chengjun Sun, Biao Lu, Yu Liu, Yaqin Zhang, Haiyan Wei, Xu Hu, Pei Hu, Qian Zhao, Yanling Liu, Kan Ye, Kan Wang, Zaiyan Gu, Zheng Liu, Jin Ye, Hongxiao Zhang, Hong Zhu, Zhihong Jiang, Yanjie Liu, Naijun Wan, Chengming Yan, Jianying Yin, Lirong Ying, Feng Huang, Qingjin Yin, Li Xi, Feihong Luo, Ruoqian Cheng
Formato: article
Lenguaje:EN
Publicado: Frontiers Media S.A. 2021
Materias:
growth hormone deficiency
PEGylated recombinant human growth hormone
PEG-rhGH
IGF-2
children
Diseases of the endocrine glands. Clinical endocrinology
RC648-665
Acceso en línea:https://doaj.org/article/342716233f3f4e22bd958dab3aed79f3
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Ejemplares similares